Evotec SE
Evotec SE (EVOTF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
evotf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Evotec SE (EVOTF) measures how much investors pay for each dollar of the company's trailing earnings. EVOTF's current PE ratio of N/A is calculated by dividing its stock price of $6.69 by its TTM earnings per share of -$1.09.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 10 fiscal years · Front-end computedMinQ1 · 25%63.8x
MedianQ3 · 75%685.3x
Max
At N/A, EVOTF's current P/E is lower than in 0% of its annual fiscal year readings over the past 10 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Evotec SEYou EVOTF | $1.2B | N/A | — | -$1.09 |
 BioGaia AB (publ) BIOGY | $1.1B | 30.83x | +66.2% | $3.29 |
 China Traditional Chinese Medicine Holdings Co. Limited CHIZF | $1.4B | N/A | — | -$0.07 |
 Cosmo Pharmaceuticals N.V. CMOPF | $1.5B | N/A | — | -$0.23 |
 Genomma Lab Internacional, S.A.B. de C.V. GNMLF | $929M | 11.58x | -37.6% | $1.65 |
 Kissei Pharmaceutical Co., Ltd. KSPHF | $1.3B | 12.26x | -33.9% | $333.61 |
 SSY Group Limited LJUIF | $1.2B | 19.53x | +5.3% | $0.16 |
Industry Average 4 peers with valid PE | — | 18.55x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.58 | — | |
2024-12-31 FY2024 | — | $-1.11 | — | |
2023-12-31 FY2023 | — | $-0.47 | — | |
2022-12-31 FY2022 | — | $-0.99 | — | |
2021-12-31 FY2021 | 32.65x | $1.30 | -95.2% | |
2020-12-31 FY2020 | 685.31x | $0.04 | +843.9% | |
2019-12-31 FY2019 | 72.61x | $0.25 | +104.0% | |
2018-12-31 FY2018 | 35.60x | $0.57 | -55.4% | |
2017-12-31 FY2017 | 79.78x | $0.17 | +237.0% | |
2016-12-31 FY2016 | 23.68x | $0.21 | -20.0% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Evotec SE (EVOTF) measures how much investors pay for each dollar of the company's trailing earnings. EVOTF's current PE ratio of N/A is calculated by dividing its stock price of $6.69 by its TTM earnings per share of -$1.09.
Frequently asked questions
EVOTF pe ratio · 6 questionsEVOTF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $6.69 and TTM EPS of -$1.09. Data sourced from Financial Modeling Prep via EVOTF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Evotec SE SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08